PDF(Pubmed)
Abstract：
UNASSIGNED: : This study tried to observe clinical benefit of aripiprazole augmentation (ARPA) treatment for major depressive disorder with anxious distress (MDDA) in routine practice.
UNASSIGNED: : Retrospective chart review (n = 41) was conducted for clinical benefit of ARPA in patients with MDDA in routine practice. The primary endpoint was the mean change of Hamilton Anxiety Rating scale (HAMA) total scores from baseline to the endpoint. Additional secondary endpoints were also retrieved.
UNASSIGNED: : The changes of primary endpoint HAMA (t = 5.731, -4.6, p = 0.001), and secondary endpoints including Hamilton Depression Rating scale (HAMD, t = 4.284, -3.4, p ＜ 0.001), Clinical Global Impression-Clinical Benefit (CGI-CB, -0.9, t = 1.821, p = 0.026), and Clinical Global Impression Score-Severity (CGI-S, t = 3.556, -0.4, p ＜ 0.001) scores were also significantly improved during the study. No significant adverse events were observed.
UNASSIGNED: : This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
UNASSIGNED: : Retrospective chart review (n = 41) was conducted for clinical benefit of ARPA in patients with MDDA in routine practice. The primary endpoint was the mean change of Hamilton Anxiety Rating scale (HAMA) total scores from baseline to the endpoint. Additional secondary endpoints were also retrieved.
UNASSIGNED: : The changes of primary endpoint HAMA (t = 5.731, -4.6, p = 0.001), and secondary endpoints including Hamilton Depression Rating scale (HAMD, t = 4.284, -3.4, p ＜ 0.001), Clinical Global Impression-Clinical Benefit (CGI-CB, -0.9, t = 1.821, p = 0.026), and Clinical Global Impression Score-Severity (CGI-S, t = 3.556, -0.4, p ＜ 0.001) scores were also significantly improved during the study. No significant adverse events were observed.
UNASSIGNED: : This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
摘要：
■：本研究试图在常规实践中观察阿立哌唑增强（ARPA）治疗伴有焦虑困扰的重度抑郁症（MDDA）的临床益处。
■：进行回顾性图表回顾（n=41），以便在常规实践中对MDDA患者进行ARPA的临床益处。主要终点是汉密尔顿焦虑量表（HAMA）总分从基线到终点的平均变化。还检索了其他次要终点。
■：主要终点HAMA的变化（t=5.731，-4.6，p=0.001），和次要终点，包括汉密尔顿抑郁量表(HAMD，t=4.284,-3.4,p＜0.001),临床总体印象-临床效益(CGI-CB，-0.9，t=1.821，p=0.026），和临床总体印象评分-严重程度(CGI-S，t=3.556,-0.4,p＜0.001)评分在研究期间也显著提高。没有观察到显著的不良事件。
■：这项研究表明，在常规实践中，ARPA治疗对MDDA患者的额外益处。然而,充分的动力和良好的对照研究对于概括目前的研究结果是必要的.
■：进行回顾性图表回顾（n=41），以便在常规实践中对MDDA患者进行ARPA的临床益处。主要终点是汉密尔顿焦虑量表（HAMA）总分从基线到终点的平均变化。还检索了其他次要终点。
■：主要终点HAMA的变化（t=5.731，-4.6，p=0.001），和次要终点，包括汉密尔顿抑郁量表(HAMD，t=4.284,-3.4,p＜0.001),临床总体印象-临床效益(CGI-CB，-0.9，t=1.821，p=0.026），和临床总体印象评分-严重程度(CGI-S，t=3.556,-0.4,p＜0.001)评分在研究期间也显著提高。没有观察到显著的不良事件。
■：这项研究表明，在常规实践中，ARPA治疗对MDDA患者的额外益处。然而,充分的动力和良好的对照研究对于概括目前的研究结果是必要的.
